Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) generates a steady flow of news as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. News coverage on this page centers on its internal pipeline, royalty-bearing collaborations, corporate strategy and legal developments.
Investors following ANAB news will see updates on rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial in rheumatoid arthritis and has been evaluated in ulcerative colitis, as well as early-stage programs ANB033 and ANB101. Company announcements describe clinical data readouts, safety and efficacy findings, and decisions to advance or discontinue specific trials, such as the discontinuation of a Phase 2 ulcerative colitis study after not meeting primary and key secondary endpoints at Week 12.
Another key news theme is AnaptysBio’s financial collaborations. Releases detail royalty and milestone expectations from Jemperli (dostarlimab-gxly), the PD-1 antagonist licensed to GSK through Tesaro, and from imsidolimab, the IL-36 receptor antagonist licensed to Vanda Pharmaceuticals. Updates from partners, such as Vanda’s Biologics License Application submission for imsidolimab, also feature prominently because AnaptysBio holds the underlying license.
Corporate and capital allocation developments appear in ANAB news as well, including the company’s intent to separate its biopharma operations from its substantial royalty assets by the end of 2026 and board-authorized stock repurchase plans. Legal and regulatory items, such as AnaptysBio’s litigation with Tesaro and GSK over the Jemperli collaboration and related SEC Form 8-K filings, also contribute to the news flow. This page aggregates these announcements so readers can track how clinical results, royalty assets, strategic separation plans and legal proceedings may shape AnaptysBio’s trajectory over time.
Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.
Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.
Anaptys (Nasdaq: ANAB) reported Q3 2025 results and announced intent to separate its biopharma operations from its royalty management business by year-end 2026 to unlock value across two public companies. The company expects to accrue a one-time $75 million commercial milestone in Q4 2025 when GSK's Jemperli reaches $1 billion in worldwide sales and cites >$390 million in annualized royalties at GSK peak-sales guidance of >$2.7 billion.
Operationally, Anaptys highlighted rosnilimab Phase 2b RA data and expects top-line Week-12 UC Phase 2 data in Nov/Dec 2025; ANB033 Phase 1b in celiac initiated with data expected in Q4 2026. Cash and investments were $256.7 million at Sept 30, 2025, with ~3.34M shares repurchased (~10.9% outstanding) for $65.2 million.
Anaptys (Nasdaq: ANAB) reported late-breaking Phase 2b results for rosnilimab in rheumatoid arthritis on Oct 29, 2025, from a global 424-patient trial presented at ACR Convergence 2025. Primary Week 12 efficacy on DAS28-CRP and ACR20 was confirmed and responses deepened by Week 28, including CDAI low disease activity and CDAI remission, independent of prior advanced therapies including JAK inhibitors.
Responses remained durable for at least three months off drug. Safety through Week 38 showed rosnilimab was well-tolerated with no treatment-related serious adverse events, no malignancies, and no deaths; Tph cells were reduced by >90% by Week 6.
Anaptys (NASDAQ: ANAB) announced that complete Phase 2b data for rosnilimab in rheumatoid arthritis will be presented as a late-breaking oral at ACR Convergence 2025 in Chicago on Oct 29, 2025 from 8:00–9:30am CT.
The company described rosnilimab as a pathogenic T cell depleter that produced a compelling safety and tolerability profile and JAK-like efficacy through six months, with effects that were reported as durable for at least three months off-drug. Paul Emery, M.D., University of Leeds, will present (Abstract ID 2215555). The presentation will be available for download from the company website after the session.
AnaptysBio (NASDAQ:ANAB) announced a virtual investor event scheduled for October 14, 2025, at 4:30 PM ET to discuss ANB033, their CD122 antagonist therapeutic candidate. The presentation will feature Dr. Joseph A. Murray from Mayo Clinic alongside the company's management team.
The event will cover three key areas: ANB033's mechanism of action as a CD122 receptor antagonist, preclinical and initial Phase 1a data from healthy volunteers, and celiac disease biology along with Phase 1b trial design. A Q&A session will follow the presentation, with a live webcast available on the company's investor relations website.
AnaptysBio (NASDAQ:ANAB) announced plans to split into two independent, publicly traded companies by year-end 2026. The first entity, temporarily named Royalty Management Co, will manage royalties from collaborations including GSK's Jemperli (generating $482M in 1H 2025) and Vanda's imsidolimab. The second entity, Biopharma Co, will focus on developing immunology therapeutics, including rosnilimab, ANB033, and ANB101.
Key financials include Jemperli's tiered royalties of 8-25% on net sales, with GSK projecting peak sales of £2 billion ($2.7B). The Vanda collaboration could yield up to $35M in milestones plus 10% royalties. Current Jemperli royalties are directed to Sagard until reaching $600M by 2031 or $675M thereafter, with an estimated $250M accrued through 2025.
AnaptysBio (Nasdaq: ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in September 2025.
The company's leadership, including CEO Daniel Faga, will participate in fireside chats and one-on-one investor meetings at the Cantor Global Healthcare Conference (Sept. 3), Wells Fargo Healthcare Conference (Sept. 4), and Stifel Virtual Immunology and Inflammation Forum (Sept. 16). All sessions will be available via webcast on the company's investor relations website.
AnaptysBio (NASDAQ:ANAB) reported Q2 2025 financial results and significant clinical progress. The company announced positive Phase 2b data for rosnilimab in rheumatoid arthritis, showing JAK-like efficacy and durable responses. Enrollment was completed for the Phase 2 ulcerative colitis trial, with top-line data expected in Q4 2025.
Financial highlights include $293.7M in cash as of June 30, 2025, collaboration revenue of $22.3M for Q2, and a net loss of $38.6M. The company expects to trigger a $75M milestone payment from GSK when Jemperli reaches $1B in annual sales. AnaptysBio has repurchased 2.85M shares (9.3%) under its stock buyback program and maintains cash runway through 2027.
The company plans to initiate a Phase 1b trial for ANB033 in celiac disease by Q4 2025 and continues Phase 1 trials for ANB033 and ANB101 in healthy volunteers.
AnaptysBio (NASDAQ: ANAB) has announced it will host an investor call and webcast on June 3, 2025 to present updated data from its global Phase 2b RENOIR clinical trial. The trial evaluates rosnilimab, a PD-1+ T cells depleter and agonist, for treating moderate-to-severe rheumatoid arthritis.
The presentation will feature distinguished speakers including Paul Emery, M.D. from the University of Leeds and Jonathan Graf, M.D. from UCSF. Following the data release, company executives led by CEO Daniel Faga will participate in two major investor conferences: the Jefferies Global Healthcare Conference on June 5 and the Goldman Sachs Global Healthcare Conference on June 11, 2025.